5wl1 - Revision history

OCA at 08:53, 30 September 2020

OCA — Wed, 30 Sep 2020 08:53:41 GMT

←Older revision		Revision as of 08:53, 30 September 2020
Line 1:		Line 1:

	==Crystal Structure of Human CD1b in Complex with PG==		==Crystal Structure of Human CD1b in Complex with PG==
-	<StructureSection load='5wl1' size='340' side='right' caption='[[5wl1]], [[Resolution\|resolution]] 1.38Å' scene=''>	+	<StructureSection load='5wl1' size='340' side='right'caption='[[5wl1]], [[Resolution\|resolution]] 1.38Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5wl1]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WL1 OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5WL1 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5wl1]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WL1 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5WL1 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CUY:tetracosyl+octadecanoate'>CUY</scene>, <scene name='pdbligand=D3D:(19S,22R,25R)-22,25,26-trihydroxy-16,22-dioxo-17,21,23-trioxa-22lambda~5~-phosphahexacosan-19-yl+(9E)-octadec-9-enoate'>D3D</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=~~FUC~~:~~ALPHA-L-FUCOSE~~'>~~FUC~~</scene>, <scene name='pdbligand=~~IOD~~:~~IODIDE~~+ION'>~~IOD~~</scene>, <scene name='pdbligand=~~MAN~~:ALPHA-D-~~MANNOSE~~'>~~MAN~~</scene>, <scene name='pdbligand=NA:~~SODIUM+ION~~'>NA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CUY:tetracosyl+octadecanoate'>CUY</scene>, <scene name='pdbligand=D3D:(19S,22R,25R)-22,25,26-trihydroxy-16,22-dioxo-17,21,23-trioxa-22lambda~5~-phosphahexacosan-19-yl+(9E)-octadec-9-enoate'>D3D</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca.weizmann~~.~~ac.il/oca-docs~~/fgij/fg.htm?mol=5wl1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wl1 OCA], [http://pdbe.org/5wl1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5wl1 RCSB], [http://www.ebi.ac.uk/pdbsum/5wl1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5wl1 ProSAT]</span></td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CD1B ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5wl1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wl1 OCA], [http://pdbe.org/5wl1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5wl1 RCSB], [http://www.ebi.ac.uk/pdbsum/5wl1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5wl1 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 5wl1" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5wl1" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Beta-2 microglobulin 3D structures\|Beta-2 microglobulin 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Gras, S]]		[[Category: Gras, S]]
	[[Category: Rossjohn, J]]		[[Category: Rossjohn, J]]

OCA at 06:02, 1 November 2017

OCA — Wed, 01 Nov 2017 06:02:21 GMT

←Older revision		Revision as of 06:02, 1 November 2017
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5wl1 is ~~ON HOLD~~ ~~until Paper~~ Publication	+	==Crystal Structure of Human CD1b in Complex with PG==
		+	<StructureSection load='5wl1' size='340' side='right' caption='[[5wl1]], [[Resolution\|resolution]] 1.38Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5wl1]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WL1 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5WL1 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CUY:tetracosyl+octadecanoate'>CUY</scene>, <scene name='pdbligand=D3D:(19S,22R,25R)-22,25,26-trihydroxy-16,22-dioxo-17,21,23-trioxa-22lambda~5~-phosphahexacosan-19-yl+(9E)-octadec-9-enoate'>D3D</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5wl1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wl1 OCA], [http://pdbe.org/5wl1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5wl1 RCSB], [http://www.ebi.ac.uk/pdbsum/5wl1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5wl1 ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/CD1B_HUMAN CD1B_HUMAN]] Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.<ref>PMID:10981968</ref> <ref>PMID:14716313</ref> [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Human T cell autoreactivity toward lipid antigens presented by CD1 proteins can manifest in numerous diseases, including psoriasis, contact hypersensitivities, and allergies. However, the molecular mechanisms for regulating T cell autoreactivity toward lipid antigens remain unclear. We determined the basis for T cell receptor (TCR) autoreactivity toward CD1b bound to self-phospholipids. The spectrum of self-antigens captured by CD1b skews toward abundant membrane phospholipids such as phosphatidylcholine and phosphatidylethanolamine. However, TCRs can specifically recognize rare phospholipids, including phosphatidylglycerol (PG). The structure of an autoreactive TCR bound to CD1b-PG shows that discrimination occurs through a marked induced fit movement of PG so that its polar head group fits snugly into the cationic cup of the TCR. Conversely, TCR binding toward ubiquitous self-phospholipids was sterically or electrostatically repelled. Accordingly, we describe a mechanism of TCR autoreactivity toward rare phospholipids and avoidance of autoreactivity to the most abundant self-phospholipids.

-	~~Authors~~:	+	A molecular basis of human T cell receptor autoreactivity toward self-phospholipids.,Shahine A, Van Rhijn I, Cheng TY, Iwany S, Gras S, Moody DB, Rossjohn J Sci Immunol. 2017 Oct 20;2(16). pii: eaao1384. doi: 10.1126/sciimmunol.aao1384. PMID:29054999<ref>PMID:29054999</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5wl1" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Gras, S]]
		+	[[Category: Rossjohn, J]]
		+	[[Category: Shahine, A]]
		+	[[Category: Antigen presenting molecule]]
		+	[[Category: Cd1b]]
		+	[[Category: Immune system]]
		+	[[Category: Mhc]]
		+	[[Category: Pg]]
		+	[[Category: Phospholipid]]

OCA at 05:33, 25 October 2017

OCA — Wed, 25 Oct 2017 05:33:35 GMT

←Older revision		Revision as of 05:33, 25 October 2017
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5wl1 is ON HOLD	+	The entry 5wl1 is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "5wl1" [edit=sysop:move=sysop]

OCA — Wed, 27 Sep 2017 14:56:33 GMT

Protected "5wl1" [edit=sysop:move=sysop]

←Older revision

Revision as of 14:56, 27 September 2017

OCA: New page: '''Unreleased structure''' The entry 5wl1 is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 27 Sep 2017 14:56:32 GMT

New page: '''Unreleased structure''' The entry 5wl1 is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 5wl1 is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]